Goldman Sachs Alternatives led a $105m Series B round in Attovia Therapeutics.

Goldman Sachs Alternatives, an investment company, led a $105m Series B round in Attovia Therapeutics, a biotechnology company, with participation from Cormorant Capital Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, Logos Capital, Frazier Life Sciences, venBio, and Illumina Ventures. “The strong investor interest and timing of this financing underscore the rapid progress we made with Attovia’s differentiated pipeline since the company inception, and the unique potential of our proprietary platform to develop attractive, next-generation immunology product candidates. We are grateful for the support from such a strong group of investors, allowing us to advance our lead programs to the clinic in the near term, further expand our pipeline in novel bi-specifics and catalyze potential business development opportunities,” Tao Fu, Attovia CEO.